China Is Collecting DNA From Tens of Millions of Men and Boys, Using U.S. Equipment
By Sui-Lee Wee,
The New York Times
| 06. 17. 2020
Even children are pressed into giving blood samples to build a sweeping genetic database that will add to Beijing’s growing surveillance capabilities, raising questions about abuse and privacy.
The police in China are collecting blood samples from men and boys from across the country to build a genetic map of its roughly 700 million males, giving the authorities a powerful new tool for their emerging high-tech surveillance state.
They have swept across the country since late 2017 to collect enough samples to build a vast DNA database, according to a new study published on Wednesday by the Australian Strategic Policy Institute, a research organization, based on documents also reviewed by The New York Times. With this database, the authorities would be able to track down a man’s male relatives using only that man’s blood, saliva or other genetic material.
An American company, Thermo Fisher, is helping: The Massachusetts company has sold testing kits to the Chinese police tailored to their specifications. American lawmakers have criticized Thermo Fisher for selling equipment to the Chinese authorities, but the company has defended its business.
The project is a major escalation of China’s efforts to use genetics to control its people, which had been focused on tracking ethnic minorities and...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...